Ongoing immune, coagulation, and cardiac abnormalities are linked to increased post-discharge mortality in severely malnourished pediatric patients. - Takeaways - MDSpire

Ongoing immune, coagulation, and cardiac abnormalities are linked to increased post-discharge mortality in severely malnourished pediatric patients.

  • By

  • Brenda Kamau

  • Evans O. Mudibo

  • Cecillia Wechessa

  • Elisha Omer

  • Bonface M. Gichuki

  • David M. Mburu

  • Laura Mwalekwa

  • Molline Timbwa

  • Johnstone Thitiri

  • Moses M. Ngari

  • James A. Berkley

  • James M. Njunge

  • January 22, 2026

  • 0 min

Share

  • 1

    High post-discharge mortality rates in severely malnourished children are linked to ongoing immune and coagulation abnormalities.

  • 2

    Persistent inflammation and endothelial dysfunction contribute to increased mortality risk 2-6 months after hospital discharge.

  • 3

    Children with complicated severe malnutrition show prolonged dysregulation of inflammatory biomarkers post-treatment.

  • 4

    The study highlights the need for targeted post-discharge interventions to address ongoing physiological vulnerabilities.

  • 5

    Mortality risk factors include illness severity, malnutrition, young age, and socioeconomic disadvantage.

Original Source(s)

Ongoing immune, coagulation, and cardiac abnormalities are linked to increased post-discharge mortality in severely malnourished pediatric patients.

  • by Brenda Kamau, Evans O. Mudibo, Cecillia Wechessa, Elisha Omer, Bonface M. Gichuki, David M. Mburu, Laura Mwalekwa, Molline Timbwa, Johnstone Thitiri, Moses M. Ngari, James A. Berkley, James M. Njunge

  • January 22, 2026

Related Content

Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included

  • April 9, 2026

  • 2 min
Health-related quality of life in Chinese children with immune thrombocytopaenia: a multicentre study

Nonprofit buys experimental cancer drug to maintain patient access